Farther Finance Advisors’s Avidity Biosciences RNAM Stock Holding History

Farther Finance Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,398	Closed	-$101K	–	5877
2025 Q4	$101K	Buy	1,398 +1,168	+508%	+$75.4K	﹤0.01%	2342
2025 Q3	$10K	Buy	230 +105	+84%	+$4.25K	﹤0.01%	3443
2025 Q2	$3.55K	Sell	125 -68	-35%	-$2.03K	﹤0.01%	3497
2025 Q1	$5.16K	Buy	193 +25	+15%	+$779	﹤0.01%	3046
2024 Q4	$4.88K	Buy	168 +161	+2,300%	+$6.73K	﹤0.01%	2673
2024 Q3	$322	Buy	+7	New	+$304	﹤0.01%	3537
2023 Q2	–	Sell	-514	Closed	-$7.89K	–	2555
2023 Q1	$7.89K	Buy	+514	New	+$11.3K	﹤0.01%	1198

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Farther Finance Advisors's RNAM Position: Q1 2026 in Review

Farther Finance Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,398 shares — an estimated $101K sold.

Farther Finance Advisors first reported a position in RNAM in Q1 2023 and held it in 7 quarters. The position peaked at $101K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Farther Finance Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Farther Finance Advisors sold 1,398 Avidity Biosciences shares in Q1 2026, an estimated $101K.
Farther Finance Advisors first reported a position in Avidity Biosciences in Q1 2023 and held it in 7 quarters.
Farther Finance Advisors's Avidity Biosciences position peaked at $101K in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.